2026 Q2 - tulosraportti
81 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sitten · MuokattuThe response from AI about the webcast on Friday 27.11 I am uploading at least this week☺️ New research results: The company has new data showing that the technology works in living organisms, not just in cell cultures. Broader application area: The technology can potentially be used together with newer delivery systems for gene therapy. Solid Biosciences: They will provide more information about the collaboration with this biotech company. Business development: There may come interesting information about commercial opportunities and partnership collaborations. Is this share price driving? Potentially yes. The most interesting part is that Circio is already signaling new data demonstrating «in vivo proof-of-concept». This means they have achieved a form of experimental confirmation that the technology works in living organisms. However, this is not the same as documented effect in humans, and the announcement does not confirm any new licensing agreement or revenues. I interpret this as a positive research-related stock exchange announcement. Friday November 27 can be an important day for Circio shareholders, depending on how strong the new results are and what management tells about theSo the question.. how much does one dare to sell at the peaks, because I expect this to be mauled down before it gets its next upswing again
- ·5 t sitten · Muokattu
- ·7 t sittenThe positive aspect of Circio is the combination of financial leeway and a technology with multiple potential applications. The company has raised 820 million kroner in 2026 and estimates funding through 2030. This provides time for thorough development, documentation, and collaboration. As bennyz points out, five acquisitions within in-vivo cell therapy and related technologies have a combined announced maximum value of 14 billion dollars, including conditional milestones. This demonstrates that the willingness to pay for promising technologies in these markets is abundantly present. On November 27, Circio will present new preclinical in-vivo data for circVec in next-generation AAV capsids. Good results can strengthen the platform's relevance and the basis for commercial agreements. Biotech still involves risk, but Circio has gained financial room to explore the potential. It is research and the quality of future agreements that will determine value creation. Why not be optimistic and patient. It may be that we contribute to creating a better world as indicated in some previous posts.
- ·7 t sittenI find Pfizer's agreement with Starna quite interesting viewed through Circio glasses. Pfizer is paying 330 million dollars upfront, with the possibility of an additional 2.3 billion dollars in milestones for an in vivo CAR-T platform. This shows what value Big Pharma is starting to see in in vivo CAR-T, also at the preclinical stage. If Circio manages to deliver good in vivo results with its circRNA technology, it could become very interesting regarding future partnerships and licensing agreements. Will be exciting to follow the development going forward!
- ·17 t sitten14 BILLION DOLLARS. FIVE ACQUISITIONS. AND CIRCIO IS RIGHT IN THE MIDDLE OF THE TECHNOLOGY RACE. 🧬♟️🍷 Take a look at what Big Pharma has actually done: 💰 Eli Lilly → Kelonia: up to $7B. 💰 Eli Lilly → Orna: up to $2.4B. 💰 AbbVie → Capstan: $2.1B. 💰 Bristol Myers Squibb → Orbital: $1.5B. 💰 AstraZeneca → EsoBiotec: up to $1B. 14 BILLION DOLLARS in announced acquisition values within in-vivo cell therapy, CAR-T, and related RNA technologies. Just these five deals from 2025–2026. And in the broader biopharma market? Around 209 billion dollars distributed across 77 announced acquisitions in 2026 according to one industry overview. This is not small change. This is a global race for next-generation medicines. SO WHERE DOES CIRCIO STAND? 🧬 820 MILLION KRONER raised in 2026. 🧬 Financing horizon to 2030. 🧬 20+ active research collaborations. 🧬 Gen 5.2: approx. 200x higher gene expression in the heart. 95% heart specificity. Preclinical. 🧬 Heart. Eye. CNS. In-vivo CAR-T. 🧬 Acuitas. Nasdaq-listed Solid Biosciences. A top 5 pharma company. And now November 27 is confirmed: new in-vivo proof-of-concept data for circVec in next-generation AAV capsids will be presented. Read this one more time. Big Pharma is spending billions on technologies within the exact same emerging therapeutic areas. Circio is building a platform that could potentially have multiple applications in precisely these markets. No, Circio is not Kelonia or Orna. And the multi-billion-dollar acquisitions are no guarantee that circVec will succeed. BUT THAT IS PRECISELY WHERE THE OPPORTUNITY LIES. If the technology is validated, the risk may fall. If the risk falls, the bargaining power may increase. And if the right deals come along, the entire valuation may have to be reassessed. It is not a single stock exchange announcement I am investing for. It is the possibility that one confirmation makes the next one even more valuable. Consolidation? Volatility? Impatience? That is part of the risk of being early. The big money does not necessarily wait for the technology to become risk-free. It tries to secure it before the competition does. And if circVec actually delivers? Then the question one day might be why we were so obsessed with the share price between the milestones. We know what we own. 🧱♟️🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
81 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sitten · MuokattuThe response from AI about the webcast on Friday 27.11 I am uploading at least this week☺️ New research results: The company has new data showing that the technology works in living organisms, not just in cell cultures. Broader application area: The technology can potentially be used together with newer delivery systems for gene therapy. Solid Biosciences: They will provide more information about the collaboration with this biotech company. Business development: There may come interesting information about commercial opportunities and partnership collaborations. Is this share price driving? Potentially yes. The most interesting part is that Circio is already signaling new data demonstrating «in vivo proof-of-concept». This means they have achieved a form of experimental confirmation that the technology works in living organisms. However, this is not the same as documented effect in humans, and the announcement does not confirm any new licensing agreement or revenues. I interpret this as a positive research-related stock exchange announcement. Friday November 27 can be an important day for Circio shareholders, depending on how strong the new results are and what management tells about theSo the question.. how much does one dare to sell at the peaks, because I expect this to be mauled down before it gets its next upswing again
- ·5 t sitten · Muokattu
- ·7 t sittenThe positive aspect of Circio is the combination of financial leeway and a technology with multiple potential applications. The company has raised 820 million kroner in 2026 and estimates funding through 2030. This provides time for thorough development, documentation, and collaboration. As bennyz points out, five acquisitions within in-vivo cell therapy and related technologies have a combined announced maximum value of 14 billion dollars, including conditional milestones. This demonstrates that the willingness to pay for promising technologies in these markets is abundantly present. On November 27, Circio will present new preclinical in-vivo data for circVec in next-generation AAV capsids. Good results can strengthen the platform's relevance and the basis for commercial agreements. Biotech still involves risk, but Circio has gained financial room to explore the potential. It is research and the quality of future agreements that will determine value creation. Why not be optimistic and patient. It may be that we contribute to creating a better world as indicated in some previous posts.
- ·7 t sittenI find Pfizer's agreement with Starna quite interesting viewed through Circio glasses. Pfizer is paying 330 million dollars upfront, with the possibility of an additional 2.3 billion dollars in milestones for an in vivo CAR-T platform. This shows what value Big Pharma is starting to see in in vivo CAR-T, also at the preclinical stage. If Circio manages to deliver good in vivo results with its circRNA technology, it could become very interesting regarding future partnerships and licensing agreements. Will be exciting to follow the development going forward!
- ·17 t sitten14 BILLION DOLLARS. FIVE ACQUISITIONS. AND CIRCIO IS RIGHT IN THE MIDDLE OF THE TECHNOLOGY RACE. 🧬♟️🍷 Take a look at what Big Pharma has actually done: 💰 Eli Lilly → Kelonia: up to $7B. 💰 Eli Lilly → Orna: up to $2.4B. 💰 AbbVie → Capstan: $2.1B. 💰 Bristol Myers Squibb → Orbital: $1.5B. 💰 AstraZeneca → EsoBiotec: up to $1B. 14 BILLION DOLLARS in announced acquisition values within in-vivo cell therapy, CAR-T, and related RNA technologies. Just these five deals from 2025–2026. And in the broader biopharma market? Around 209 billion dollars distributed across 77 announced acquisitions in 2026 according to one industry overview. This is not small change. This is a global race for next-generation medicines. SO WHERE DOES CIRCIO STAND? 🧬 820 MILLION KRONER raised in 2026. 🧬 Financing horizon to 2030. 🧬 20+ active research collaborations. 🧬 Gen 5.2: approx. 200x higher gene expression in the heart. 95% heart specificity. Preclinical. 🧬 Heart. Eye. CNS. In-vivo CAR-T. 🧬 Acuitas. Nasdaq-listed Solid Biosciences. A top 5 pharma company. And now November 27 is confirmed: new in-vivo proof-of-concept data for circVec in next-generation AAV capsids will be presented. Read this one more time. Big Pharma is spending billions on technologies within the exact same emerging therapeutic areas. Circio is building a platform that could potentially have multiple applications in precisely these markets. No, Circio is not Kelonia or Orna. And the multi-billion-dollar acquisitions are no guarantee that circVec will succeed. BUT THAT IS PRECISELY WHERE THE OPPORTUNITY LIES. If the technology is validated, the risk may fall. If the risk falls, the bargaining power may increase. And if the right deals come along, the entire valuation may have to be reassessed. It is not a single stock exchange announcement I am investing for. It is the possibility that one confirmation makes the next one even more valuable. Consolidation? Volatility? Impatience? That is part of the risk of being early. The big money does not necessarily wait for the technology to become risk-free. It tries to secure it before the competition does. And if circVec actually delivers? Then the question one day might be why we were so obsessed with the share price between the milestones. We know what we own. 🧱♟️🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
81 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 8.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sitten · MuokattuThe response from AI about the webcast on Friday 27.11 I am uploading at least this week☺️ New research results: The company has new data showing that the technology works in living organisms, not just in cell cultures. Broader application area: The technology can potentially be used together with newer delivery systems for gene therapy. Solid Biosciences: They will provide more information about the collaboration with this biotech company. Business development: There may come interesting information about commercial opportunities and partnership collaborations. Is this share price driving? Potentially yes. The most interesting part is that Circio is already signaling new data demonstrating «in vivo proof-of-concept». This means they have achieved a form of experimental confirmation that the technology works in living organisms. However, this is not the same as documented effect in humans, and the announcement does not confirm any new licensing agreement or revenues. I interpret this as a positive research-related stock exchange announcement. Friday November 27 can be an important day for Circio shareholders, depending on how strong the new results are and what management tells about theSo the question.. how much does one dare to sell at the peaks, because I expect this to be mauled down before it gets its next upswing again
- ·5 t sitten · Muokattu
- ·7 t sittenThe positive aspect of Circio is the combination of financial leeway and a technology with multiple potential applications. The company has raised 820 million kroner in 2026 and estimates funding through 2030. This provides time for thorough development, documentation, and collaboration. As bennyz points out, five acquisitions within in-vivo cell therapy and related technologies have a combined announced maximum value of 14 billion dollars, including conditional milestones. This demonstrates that the willingness to pay for promising technologies in these markets is abundantly present. On November 27, Circio will present new preclinical in-vivo data for circVec in next-generation AAV capsids. Good results can strengthen the platform's relevance and the basis for commercial agreements. Biotech still involves risk, but Circio has gained financial room to explore the potential. It is research and the quality of future agreements that will determine value creation. Why not be optimistic and patient. It may be that we contribute to creating a better world as indicated in some previous posts.
- ·7 t sittenI find Pfizer's agreement with Starna quite interesting viewed through Circio glasses. Pfizer is paying 330 million dollars upfront, with the possibility of an additional 2.3 billion dollars in milestones for an in vivo CAR-T platform. This shows what value Big Pharma is starting to see in in vivo CAR-T, also at the preclinical stage. If Circio manages to deliver good in vivo results with its circRNA technology, it could become very interesting regarding future partnerships and licensing agreements. Will be exciting to follow the development going forward!
- ·17 t sitten14 BILLION DOLLARS. FIVE ACQUISITIONS. AND CIRCIO IS RIGHT IN THE MIDDLE OF THE TECHNOLOGY RACE. 🧬♟️🍷 Take a look at what Big Pharma has actually done: 💰 Eli Lilly → Kelonia: up to $7B. 💰 Eli Lilly → Orna: up to $2.4B. 💰 AbbVie → Capstan: $2.1B. 💰 Bristol Myers Squibb → Orbital: $1.5B. 💰 AstraZeneca → EsoBiotec: up to $1B. 14 BILLION DOLLARS in announced acquisition values within in-vivo cell therapy, CAR-T, and related RNA technologies. Just these five deals from 2025–2026. And in the broader biopharma market? Around 209 billion dollars distributed across 77 announced acquisitions in 2026 according to one industry overview. This is not small change. This is a global race for next-generation medicines. SO WHERE DOES CIRCIO STAND? 🧬 820 MILLION KRONER raised in 2026. 🧬 Financing horizon to 2030. 🧬 20+ active research collaborations. 🧬 Gen 5.2: approx. 200x higher gene expression in the heart. 95% heart specificity. Preclinical. 🧬 Heart. Eye. CNS. In-vivo CAR-T. 🧬 Acuitas. Nasdaq-listed Solid Biosciences. A top 5 pharma company. And now November 27 is confirmed: new in-vivo proof-of-concept data for circVec in next-generation AAV capsids will be presented. Read this one more time. Big Pharma is spending billions on technologies within the exact same emerging therapeutic areas. Circio is building a platform that could potentially have multiple applications in precisely these markets. No, Circio is not Kelonia or Orna. And the multi-billion-dollar acquisitions are no guarantee that circVec will succeed. BUT THAT IS PRECISELY WHERE THE OPPORTUNITY LIES. If the technology is validated, the risk may fall. If the risk falls, the bargaining power may increase. And if the right deals come along, the entire valuation may have to be reassessed. It is not a single stock exchange announcement I am investing for. It is the possibility that one confirmation makes the next one even more valuable. Consolidation? Volatility? Impatience? That is part of the risk of being early. The big money does not necessarily wait for the technology to become risk-free. It tries to secure it before the competition does. And if circVec actually delivers? Then the question one day might be why we were so obsessed with the share price between the milestones. We know what we own. 🧱♟️🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 989 | ||
| 7 646 | ||
| 24 999 | ||
| 1 611 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt






